BigHat Biosciences Partners with Janssen Biotech to Advance Antibody Discovery with AI-Driven Platform

BigHat’s Milliner platform and Janssen Biotech's expertise to expedite the design of high-quality antibodies for Neuroscience therapeutic targets.

BigHat Biosciences, a leading biotechnology company specializing in AI/machine learning-guided antibody discovery and development, has announced a strategic collaboration with Janssen Biotech Inc., a subsidiary of Johnson & Johnson. The partnership aims to revolutionize antibody discovery by combining BigHat’s innovative technology with Janssen Biotech's drug discovery, clinical development, and data science capabilities.

The primary objective of this collaboration is to harness the combined expertise of both companies to guide the design and selection of high-quality antibodies targeting multiple Neuroscience therapeutic targets. The collaboration will leverage BigHat’s Milliner platform, a cutting-edge suite of machine learning technologies integrated with a high-speed wet lab, to streamline the antibody discovery process.

BigHat’s Milliner platform integrates synthetic biology-based high-speed wet lab capabilities with advanced machine learning technologies, offering a comprehensive solution for antibody discovery and engineering. This full-stack platform enables the engineering of antibodies with complex functions and improved biophysical properties, making it easier to design therapeutic proteins for a wide range of conditions, from chronic illnesses to life-threatening diseases. Moreover, the platform accelerates candidate discovery and validation, reducing the time and resources required for drug development.

With this partnership, BigHat Biosciences and Janssen Biotech aim to accelerate the development of innovative therapies that address unmet medical needs, marking a significant advancement in the field of antibody discovery and design.